Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Chara, Luis ^a   Sánchez Atrio, Ana ^b   Pérez, Ana ^b   Cuende, Eduardo ^b   Albarrán, Fernando ^b   Turrión, Ana ^b   Chevarria, Julio ^a   Sánchez, Miguel A ^a   Monserrat, Jorge ^a   de la Hera, Antonio ^a   Prieto, Alfredo ^a   Sanz, Ignacio ^c   Diaz, David ^a   Alvarez Mon, Melchor ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CD14 ANTIGEN; CD16 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CX3CR1; FOLIC ACID; METHOTREXATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL COUNT; CELL POPULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONOCYTE; PREDICTION; PREDICTIVE VALUE; PROCESS MONITORING; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864273022     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3928     Document Type: Article

References (39)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
2. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009, 23:111-124. 10.2165/00063030-200923020-00004, 19489652.
3. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009, 21:224-230. 10.1097/BOR.0b013e3283295fec, 19365268.
4. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011, 23:245-251. 10.1097/BOR.0b013e3283454124, 21427579.
5. Bergman MJ. Assessing adequate treatment response in patients with rheumatoid arthritis. Clin Ther 2009, 31:1219-1231. 10.1016/j.clinthera.2009.06.005, 19695389.
6. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-92. 10.1146/annurev.immunol.021908.132557, 19132917.
7. Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006, 8:R152. 10.1186/ar2046, 1779441, 16987426.
8. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001, 69:11-20.
9. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964. 10.1038/nri1733, 16322748.
10. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82. 10.1016/S1074-7613(03)00174-2, 12871640.
11. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 21:e74-80.
12. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007, 19:289-295. 10.1097/BOR.0b013e32805e87ae, 17414958.
13. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol Life Sci 2010, 67:2685-2693. 10.1007/s00018-010-0375-x, 20437077.
14. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. 2):ii13-ii16. 1766753, 14532140.
15. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 2007, 36:411-417. 10.1080/03009740701607067, 18092260.
16. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011, 162:785-791. 10.1111/j.1476-5381.2010.01099.x, 3042190, 21039421.
17. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926. 10.1136/ard.2006.065615, 1955110, 17301106.
18. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, (39):34-40.
19. González VM, Stewart A, Ritter PL, Lorig K. Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum 1995, 38:1429-1446. 10.1002/art.1780381010, 7575693.
20. Böyum AJ. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968, 21:77-89. 10.3109/00365516809076979, 5637478.
21. Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739. 10.1136/ard.2006.066761, 1954645, 17329305.
22. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008, 10:R50. 10.1186/ar2419, 2483439, 18454843.
23. Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 2010, 87:311-321. 10.1038/clpt.2009.244, 20032971.
24. Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009, 60:3217-3224. 10.1002/art.24913, 19877042.
25. Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76. 10.1186/ar2706, 2714123, 19460157.
26. Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-195. 10.1111/j.1365-2249.2008.03691.x, 2492901, 18549443.
27. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB. Synovial macrophage depletion with clodronatecontaining liposomes in rheumatoid arthritis. Arthritis Rheum 2000, 43:1951-1959. 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K, 11014344.
28. Kashiwagi N, Nakano M, Saniabadi AR, Adachi M, Yoshikawa T. Anti-inflammatory effect of granulocyte and monocyte adsorption apheresis in a rabbit model of immune arthritis. Inflammation 2002, 26:199-205. 10.1023/A:1016523914161, 12184634.
29. Buchan GS, Palmer DG, Gibbins BL. The response of human peripheral blood mononuclear phagocytes to rheumatoid arthritis. J Leukoc Biol 1985, 37:221-230.
30. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279. 10.1016/j.pharmthera.2007.10.001, 18155297.
31. Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, Fitzgerald O, Kirkham BW, McInnes IB, Smith M, Ulfgren AK, Veale DJ, Tak PP. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol 2007, 34:620-622.
32. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor a blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47. 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L, 10643698.
33. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442. 10.1038/nri2094, 17525752.
34. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72. 10.1002/art.20764, 15641091.
35. Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005, 115:250-259. 10.1016/j.clim.2005.01.007, 15893692.
36. Meugnier E, Coury F, Tebib J, Ferraro-Peyret C, Rome S, Bienvenu J, Vidal H, Sibilia J, Fabien N. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. Physiol Genomics 2011, 43:365-371. 10.1152/physiolgenomics.00127.2010, 21266503.
37. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pre-treatment TNFa expression in the synovium. Ann Rheum Dis 2008, 67:1139-1144. 10.1136/ard.2007.080440, 2564801, 18055470.
38. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009, 60:1210-1221. 10.1002/art.24505, 19404968.
39. Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One 2010, 5:e11310. 10.1371/journal.pone.0011310, 2892481, 20593016.